Los Angeles Capital Management LLC Has $1.76 Million Stake in Progyny, Inc. (NASDAQ:PGNY)

Los Angeles Capital Management LLC decreased its stake in Progyny, Inc. (NASDAQ:PGNY) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,013 shares of the company’s stock after selling 3,406 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Progyny were worth $1,755,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PGNY. Charles Schwab Investment Management Inc. raised its position in shares of Progyny by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 630,648 shares of the company’s stock worth $21,455,000 after purchasing an additional 46,144 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Progyny during the third quarter worth about $512,000. Deutsche Bank AG raised its position in shares of Progyny by 12.7% during the third quarter. Deutsche Bank AG now owns 42,029 shares of the company’s stock worth $1,430,000 after purchasing an additional 4,738 shares during the period. Rhumbline Advisers raised its position in shares of Progyny by 5.0% during the third quarter. Rhumbline Advisers now owns 261,569 shares of the company’s stock worth $8,899,000 after purchasing an additional 12,366 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Progyny by 14.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 33,353 shares of the company’s stock worth $1,150,000 after purchasing an additional 4,253 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PGNY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $48.00 price target on shares of Progyny in a research report on Thursday, May 16th. SVB Leerink assumed coverage on Progyny in a research report on Monday, February 26th. They issued an “outperform” rating and a $49.00 target price on the stock. BTIG Research dropped their target price on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. KeyCorp lowered Progyny from an “overweight” rating to a “sector weight” rating in a research report on Friday, May 10th. Finally, Truist Financial dropped their target price on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.11.

Progyny Stock Up 2.1 %

PGNY stock opened at $25.86 on Friday. The business has a 50 day moving average price of $29.16 and a two-hundred day moving average price of $34.51. The company has a market cap of $2.46 billion, a price-to-earnings ratio of 42.39, a P/E/G ratio of 1.64 and a beta of 1.46. Progyny, Inc. has a twelve month low of $23.90 and a twelve month high of $44.95.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The firm had revenue of $278.08 million during the quarter, compared to the consensus estimate of $289.41 million. During the same period last year, the company earned $0.18 earnings per share. The business’s revenue was up 7.6% compared to the same quarter last year. On average, equities research analysts anticipate that Progyny, Inc. will post 0.73 EPS for the current fiscal year.

Insider Transactions at Progyny

In other news, President Michael E. Sturmer sold 4,515 shares of Progyny stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the transaction, the president now directly owns 380,038 shares in the company, valued at approximately $12,142,214.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, President Michael E. Sturmer sold 4,515 shares of Progyny stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the transaction, the president now directly owns 380,038 shares in the company, valued at approximately $12,142,214.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman David J. Schlanger sold 2,597 shares of Progyny stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $37.65, for a total value of $97,777.05. Following the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at $3,249,646.80. The disclosure for this sale can be found here. In the last three months, insiders sold 96,944 shares of company stock worth $3,634,112. 12.30% of the stock is owned by company insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.